Analysis of results from international trials question whether current aspirin recommendations apply to all patients.
Researchers in heart disease have identified a group of patients for whom international aspirin use guidelines for heart health may not be applicable.
In a study published in the renowned medical journal Circulation, the findings of a review of data from three clinical trials challenge current best practices for the use of the drug for primary prevention of heart disease or stroke — otherwise known as atherosclerotic cardiovascular disease.
The research examined the results from clinical trials involving more than 47,000 patients in 10 countries, including the US, the UK, and Australia, which were published in 2018.
Subgroup Analysis Reveals New Insights
The analysis focused on findings for a subgroup of 7,222 patients who were already taking aspirin before the three trials commenced. Those studied were at increased risk for cardiovascular disease and were taking aspirin to prevent the first occurrence of a heart attack or stroke.
The data showed a higher risk of heart disease or stroke – 12.5% versus 10.4% – for patients who were on aspirin before the trials and who then stopped, compared to those who stayed on the drug.
Analyses also found no significant statistical difference in the risk for major bleeding between the two groups of patients.
Expert Perspectives and Guidelines Shift
The research was led by Professor J. William McEvoy, Established Professor of Preventive Cardiology at University of Galway and Consultant Cardiologist at Saolta University Health Care Group, in collaboration with researchers in University of Tasmania and Monash University, Melbourne.
Professor McEvoy said: “We challenged the notion that aspirin discontinuation is a one-size-fits-all approach.”
The research team noted results from observational studies which suggest a 28% higher risk of heart disease or stroke among adults who were prescribed aspirin to reduce the risk for a first heart attack or stroke, but who subsequently chose to stop taking the aspirin without being told to do so by their doctor.
Based in large part on three major clinical trials published in 2018, international guidelines no longer recommend the routine use of aspirin to prevent the first occurrence of heart attack or stroke.
Importantly, aspirin remains recommended for high-risk adults who have already had a heart disease or stroke event, to reduce the risk of a second event.
The move away from primary prevention aspirin in recent guidelines is motivated by the increased risk of major bleeding seen with this common medication in the three trials, albeit major bleeding is relatively uncommon on aspirin and was most obvious only among trial participants who were started on aspirin during the trial, rather than those who were previously taking aspirin safely.
Continuing Aspirin: A Balanced Approach
These trials primarily tested the effect of starting aspirin among adults who have not previously been treated with the drug to reduce the risk of atherosclerotic cardiovascular disease. Less is known about what to do in the common scenario of adults who are already safely taking aspirin for primary prevention.
Professor McEvoy said: “Our findings of the benefit of aspirin in reducing heart disease or stroke without an excess risk of bleeding in some patients could be due to the fact that adults already taking aspirin without a prior bleeding problem are inherently lower risk for a future bleeding problem from the medication. Therefore, they seem to get more of the benefits of aspirin with less of the risks.
“These results are hypothesis-generating, but at present are the best available data. Until further evidence becomes available, it seems reasonable that persons already safely treated with low-dose aspirin for primary prevention may continue to do so, unless new risk factors for aspirin-related bleeding develop.”
Reference: “Outcomes After Aspirin Discontinuation Among Baseline Users in Contemporary Primary Prevention Aspirin Trials: A Meta-Analysis” by Ruth Campbell, Mark R. Nelson, John J. McNeill and John W. McEvoy, 26 February 2024, Circulation.
OneForumNews1
0 Comments